Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugarbaker, D. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sugarbaker, D. J.
(Chest. 1999;116:443S.)
© 1999 American College of Chest Physicians

Introduction: Multimodality Therapy of Chest Malignancies—Update ‘98*

David J. Sugarbaker, MD, FCCP

* From the Division of Thoracic Surgery, Brigham and Women’s Hospital, Boston, MA

Correspondence to: David J. Sugarbaker, MD, FCCP, Division of Thoracic Surgery, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115.


    Introduction
 TOP
 Introduction
 
The "Multimodality Therapy of Chest Malignancies" course was a tremendous success. I was personally pleased by the quality and scope of the faculty presentations and registrants’ participation. Since the first course in 1990, we have advocated the concept of surgeons, radiotherapists, and medical oncologists working together in the primary evaluation and treatment of patients with thoracic malignancies. What was a concept has become reality in a number of major medical centers across the United States. The advent of multidisciplinary clinics for the evaluation of patients with primary malignancies is providing improved care and will undoubtedly lead to better outcomes for patients. The latest advances in each field reach patients quickly in a multimodality approach.

As in the past, this year’s course provided a forum for intensive interaction by leaders in the field. We instructed on and examined diagnosis and therapy for esophageal cancer, non-small cell lung cancer, small cell lung cancer, mesothelioma, and the solitary pulmonary nodule, and we looked at the high-risk patient. In addition, we discussed tobacco and public health, a continuing timely subject for us.

I personally invite the readers of this supplement to write to me with comments or suggestions about the course or the CHEST supplement.





This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugarbaker, D. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sugarbaker, D. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS